EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The prognostic role of circulating CA19–9 and CEA in patients with colorectal cancer

Mathias H Gramkow, Camilla S Mosgaard, Jakob V Schou, Ellen Hein Nordvig, Troels Gammeltoft Dolin, Jakob Lykke, Dorte L Nielsen, Per Pfeiffer, Camilla Qvortrup, Mette K Yilmaz, Ole Larsen, Stig E Bojesen und 2 weitere

Cancer Treatment and Research Communications · 2025

DOI: 10.1016/j.ctarc.2025.100907 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Mathias H Gramkow und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; Danish Dementia Research Center, Department of Neurolo…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Carcinoembryonic Antigen, CA-19-9 Antigen, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Herlev Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Carcinoembryonic antigen (CEA) is the only prognostic circulating biomarker used in clinical practice for recurrence free (RFS), progression free (PFS) and overall survival (OS) in patients with colorectal cancer (CRC). Not all CRC tumors express this protein and carbohydrate antigen (CA)19-9 has been proposed as an adjunctive in prognostication. We aimed to test if CA19-9 yielded additional information to CEA regarding prognosis. PATIENTS AND METHODS: We included 886 patients with CRC across eight clinical cohorts. Preoperative serum samples were collected from 376 patients with stage I-III CRC and from 510 with metastatic (m)CRC before 1st (n = 233), 3rd (n = 178) and 3rd/4th (n = 99) line chemotherapy. CA19-9 and CEA were determined by routine assays, the values were log-2 transformed and entered as variables in Cox regression models with RFS (stage I-III), PFS and OS as the outcomes, adjusted for age, sex, and site of primary tumor and mutual adjustment between CA199 and CEA. Random effects meta-analyses were conducted for stage I-III,1st line, and 3rd/4th line mCRC cohorts separately. RESULTS: Meta-analyses showed that higher pre-treatment CA19-9 and CEA were associated with shorter RFS (CA19-9: hazard ratio per doubling of concentration (HR)=1.20, 95 % confidence interval (CI) 1.05-1.38; CEA: HR=1.22, 95 % CI 1.05-1.41) in stage I-III CRC. Only higher CEA was associated with shorter OS in 1st line mCRC (HR=1.07, 95 % CI 1.00-1.07). CONCLUSION: CA19-9 might aid in identifying patients with a high risk of recurrence after primary radical resection. Further studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsCarcinoembryonic AntigenCA-19-9 AntigenBiomarkers, TumorHumansMaleFemaleMiddle AgedPrognosisAgedAdultNeoplasm StagingNeoplasm Recurrence, Local

Stichwörter der Autor:innen

BiomarkerCA19–9CEAColorectal cancerPrognosis

Substanzen

Carcinoembryonic AntigenCA-19-9 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; Danish Dementia Research Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denma…
  • Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Department of Medicine, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Department of Gastrointestinal Surgery, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
  • Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Oncology, Odense University Hospital, Odense, Denmark.

Förderung

  • Herlev Hospital

Zitieren

APA

Gramkow, M. H., Mosgaard, C. S., Schou, J. V., Nordvig, E. H., Dolin, T. G., Lykke, J., Nielsen, D. L., Pfeiffer, P., Qvortrup, C., Yilmaz, M. K., Larsen, O., Bojesen, S. E., Jensen, B. V., & Johansen, J. S. (2025). The prognostic role of circulating CA19–9 and CEA in patients with colorectal cancer. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100907

Vancouver

Gramkow MH, Mosgaard CS, Schou JV, Nordvig EH, Dolin TG, Lykke J, et al. The prognostic role of circulating CA19–9 and CEA in patients with colorectal cancer. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100907

BibTeX
@article{Gramkow2025,
  author = {Gramkow, Mathias H and Mosgaard, Camilla S and Schou, Jakob V and Nordvig, Ellen Hein and Dolin, Troels Gammeltoft and Lykke, Jakob and Nielsen, Dorte L and Pfeiffer, Per and Qvortrup, Camilla and Yilmaz, Mette K and Larsen, Ole and Bojesen, Stig E and Jensen, Benny V and Johansen, Julia S},
  title = {The prognostic role of circulating CA19–9 and CEA in patients with colorectal cancer},
  journal = {Cancer Treatment and Research Communications},
  year = {2025},
  doi = {10.1016/j.ctarc.2025.100907}
}
Kostenlos starten →